Chimeric antigen receptor T cells persist over extended periods in patients, leading to sustained clinical remissions in advanced chronic lymphocytic leukemia.
Clinical evaluation tracks cellular dynamics in relapsed refractory chronic lymphocytic leukemia cases undergoing specialized chimeric antigen receptor T cell infusion.
Long-term persistence of functional CAR T cells supports the viability of targeted living cellular therapies for managing difficult relapsed leukemia cases.
Abstract
CAR T cells persist and sustain remissions in advanced chronic lymphocytic leukemia.